Passion to­wards science and re­search

DR SARAL THANGAM CEO & Manag­ing Di­rec­tor, Nor­wich Clin­i­cal Ser­vices, In­dia

BioSpectrum (Asia) - - Bio Content -

North Amer­i­can com­pany Nor­wich has been serv­ing the phar­ma­ceu­ti­cal in­dus­try for more than 100 years. In 2010, Nor­wich Phar­ma­ceu­ti­cals, an Alvo­gen sub­sidiary, an­nounced the for­ma­tion of Nor­wich Clin­i­cal Ser­vices to pro­vide clin­i­cal Re­search ca­pa­bil­i­ties for fur­ther ex­pand­ing the com­pany’s third party ser­vices.

Dr Saral Thangam then took the lead in set­ting up the CRO in Bengaluru, with an ex­pe­ri­enced team of pro­fes­sion­als, each hav­ing more than 15 years of ex­pe­ri­ence in clin­i­cal re­search and life sciences. Today, Nor­wich Clin­i­cal Ser­vices has state– of-the-art fa­cil­i­ties, and ex­cep­tional ex­per­tise to con­duct bioavail­abil­ity and bioe­quiv­a­lence stud­ies, clin­i­cal tri­als, drug me­tab­o­lism stud­ies, dose pro­por­tion­al­ity stud­ies, mul­ti­ple dose stud­ies and phar­ma­covig­i­lance.

Prior to join­ing Nor­wich, Dr Saral Thangam was the manag­ing di­rec­tor of Lo­tus Labs. In ad­di­tion, she has headed var­i­ous op­er­a­tional units, in­clud­ing clin­i­cal phar­ma­col­ogy, clin­i­cal de­vel­op­ment, qual­ity as­sur­ance and busi­ness de­vel­op­ment at Lo­tus. She has pub­lished and pre­sented many re­search pa­pers in sci­en­tific fo­rums in in­ter­na­tional con­fer­ences.

The com­pany started with around 20 em­ploy­ees, and un­der the ex­pert guid­ance of Saral Thangam, the num­ber has now reached close to

200. “We un­der­stand the com­plex­i­ties of drug de­vel­op­ment whether biotech, generic or pharma. Each mem­ber of our team has ex­ten­sive ex­pe­ri­ence in their area of ex­per­tise in­clud­ing lead­er­ship po­si­tions in the phar­ma­ceu­ti­cal sec­tor and con­tract re­search or­ga­ni­za­tions,” shared Dr Saral Thangam.

Dr Saral Thangam is a med­i­cal grad­u­ate from Chris­tian Med­i­cal Col­lege, Vel­lore, and has a post grad­u­ate spe­cial­iza­tion in the field of In­ter­nal Medicine. She also holds a PhD in Phys­i­ol­ogy from St. John’s Na­tional Academy of Health Sciences in In­dia. This passion to­wards science and re­search led her to the po­si­tion she cur­rently holds in her ca­reer of more than 20 years.

Nor­wich Clin­i­cal Ser­vices is fo­cused on qual­ity, with mul­ti­ple suc­cess­ful au­dits by USFDA, EMA and WHO. Their fa­cil­i­ties are cer­ti­fied by In­dian DCGI, the Brazil­ian Agency ANVISA and MOH Turkey. With an an­nual rev­enue around Rs 60 crore, Nor­wich Clin­i­cal Ser­vices has gained tremen­dous growth in the field of phar­ma­covig­i­lance over the years. “Many CROs were fac­ing prob­lems few years back due to reg­u­la­tory is­sues. Stud­ies were be­ing with­drawn from In­dia dur­ing this phase of un­cer­tainty. But we held on and fo­cused our at­ten­tion on phar­ma­covig­i­lance and drug safety, and ex­panded in this di­rec­tion”.

She is a win­ner of sev­eral awards in­clud­ing pres­ti­gious Shakun­tala Amir­c­hand Award for sig­nif­i­cant con­tri­bu­tion to bio­med­i­cal sciences by the In­dian Coun­cil of Med­i­cal Re­search (ICMR). Cur­rently, she is part of the Ex­ec­u­tive Coun­cil at the As­so­ci­a­tion of Clin­i­cal Re­search Or­gan­i­sa­tion (ACRO).

“Nor­wich also of­fers cor­po­rate train­ing ser­vices in var­i­ous ar­eas of clin­i­cal re­search for the Phar­ma­ceu­ti­cal, Clin­i­cal Re­search, Biotech­nol­ogy and IT sec­tors. In the com­ing years, we are plan­ning to work more in the di­rec­tion of biosim­i­lars”, said Dr Saral Thangam.


CEO & Manag­ing Di­rec­tor, Nor­wich Clin­i­cal Ser­vices, In­dia

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.